Taylor Morris, PA
Medical · Livingston, NJNPI 1497488183
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 344 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$836
- Lilly USA, LLC$653
- Exact Sciences$540
- GSK$500
- Bayer$490
- AstraZeneca$442
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,839100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $836 |
| Lilly USA, LLC | 44 | $653 |
| Exact Sciences | 21 | $540 |
| GSK | 31 | $500 |
| Bayer | 24 | $490 |
| AstraZeneca | 27 | $442 |
| Abbott | 15 | $297 |
| AbbVie | 21 | $288 |
| Amgen | 17 | $263 |
| Corcept Therapeutics | 13 | $218 |
| Azurity Pharmaceuticals, Inc. | 11 | $185 |
| Novartis | 12 | $180 |
| Boehringer Ingelheim | 10 | $156 |
| Pfizer | 7 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $114 |
| Gilead | 6 | $96 |
| Lundbeck LLC | 5 | $80 |
| Johnson & Johnson | 4 | $79 |
| Ardelyx, Inc. | 4 | $79 |
| Merck | 4 | $63 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| IBSA Pharma Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$5,839 in reported general payments places this provider in the 90th percentile of 573 medical providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 23 | $35,651 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $28,449 |
| EliquisApixaban | 29 | $26,735 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $19,409 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 24 | $16,123 |
| KerendiaFinerenone | 22 | $14,975 |
| FarxigaDapagliflozin Propanediol | 24 | $14,958 |
| OzempicSemaglutide | 13 | $12,640 |
| JardianceEmpagliflozin | 12 | $9,259 |
| BrilintaTicagrelor | 12 | $7,058 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $4,009 |
| Rosuvastatin Calcium | 111 | $1,700 |
| Roflumilast | 12 | $614 |
| Duloxetine Hcl | 23 | $597 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $836 | $48,29136 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $156 | $28,66826 claims |
| GSKTrelegy Ellipta | $500 | $28,44929 claims |
| PfizerEliquis | $127 | $26,73529 claims |
| AstraZenecaFarxiga, Brilinta | $442 | $22,01636 claims |
| BayerKerendia | $490 | $14,97522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 573 medical providers in New Jersey.
Other medical in Livingston
- Shannon WelnerVerona$176K
- Christinna DelgenioColts Neck$114K
- Anita FoxVerona$17K
- Therese CasasKinnelon$16K
- Joseph CollettiLinwood$16K
- Melissa MiaoKearny$14K
- Gabriela Plesek-AndiaVerona$13K
- Stephanie PhillipsMarlton$12K
- Sean AdairCape May Court House$12K
- Shane CourtneyLinwood$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.